[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
Authors: Youjun Chen, Suzy Clark, Sarajane Ross, Terence Wong, Yvonne Chen, Mark Dennis, Hartmut Koeppen, Peter Senter, Paul Polakis, Bill Mallet
Genentech, Inc., Seattle Genetics, Inc.
Abstract: MUC16 is a well-validated cell surface antigen expressed by ovarian cancer cells; the extracellular domain (ECD) is known as CA125.
Drug-conjugated antibodies (“antibodydrug conjugates” or “ADC”) directed against MUC16 might therefore have therapeutic value against this disease